Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 7, Issue 7, pp. 750-765
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 15, 2016
- Revision received October 7, 2016
- Accepted March 6, 2017
- Published first March 8, 2017.
Article Versions
- Previous version (March 8, 2017 - 12:30).
- Previous version (June 12, 2017 - 06:02).
- You are viewing the most recent version of this article.
Copyright & Usage
©2017 American Association for Cancer Research.
Author Information
- Akash Patnaik1,2,3,4,*,
- Kenneth D. Swanson5,
- Eva Csizmadia6,
- Aniruddh Solanki7,8,
- Natalie Landon-Brace7,8,
- Marina P. Gehring5,9,
- Katja Helenius10,
- Brian M. Olson3,4,
- Athalia R. Pyzer1,
- Lily C. Wang11,
- Olivier Elemento11,
- Jesse Novak12,
- Thomas B. Thornley13,
- John M. Asara14,
- Laleh Montaser15,
- Joshua J. Timmons5,
- Todd M. Morgan16,
- Yugang Wang16,
- Elena Levantini1,8,17,
- John G. Clohessy2,18,
- Kathleen Kelly19,
- Pier Paolo Pandolfi2,
- Jacalyn M. Rosenblatt1,2,
- David E. Avigan1,2,
- Huihui Ye15,
- Jeffrey M. Karp7,8,
- Sabina Signoretti12,
- Steven P. Balk1,2 and
- Lewis C. Cantley11
- 1Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Dana Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts.
- 2Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 3Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
- 4The University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
- 5Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 6Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- 7Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- 8Harvard Stem Cell Institute, Boston, Massachusetts.
- 9Laboratório de Farmacologia Aplicada, PUCRS, Porto Alegre, Brazil.
- 10Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
- 11Meyer Cancer Center, Weill Cornell Medical College, New York, New York.
- 12Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- 13Transplant Institute and Immunology Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 14Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 15Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 16Department of Urology, University of Michigan, Ann Arbor, Michigan.
- 17Institute of Biomedical Technologies, National Research Council (CNR), Pisa, Italy.
- 18Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- 19Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland.
- ↵*Corresponding Author:
Akash Patnaik, The University of Chicago, Knapp Center for Biomedical Discovery, Room 7152, 900 East 57th Street, Chicago, IL 60637. Phone: 773-834-3519; Fax: 773-834-0778; E-mail: apatnaik1{at}uchicago.edu
M.P. Gehring, K. Helenius, B.M. Olson, and A.R. Pyzer contributed equally to this article.
July 2017
Volume 7, Issue 7
Volume 7, Issue 7
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Jump to section
Advertisement